Clinical trial
Tadalafil in Subjects With Mild to Moderate Hypertension
NCT00157326 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00157326 |
|---|---|
| Title | Tadalafil in Subjects With Mild to Moderate Hypertension |
| Official title | A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | ICOS Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | tadalafil |
| Enrollment | 180 |
| Start date | Sep 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Oct 25, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: